Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 5 30 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 5 30 versus PORTIA 21.
JUNEL 1.5/30 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive